Baudax Reports Results of BX1000 in P-II Trial for Neuromuscular Blockade in Undergoing Elective Surgeries
Shots:
- The P-II clinical trial evaluating the safety & tolerability of BX1000 (at 3 doses) vs rocuronium for the neuromuscular blockade is expected to enrol ~80 adult patients undergoing elective surgery. Baudax expects to combine BX1000 + BX3000 (expected IND filing in 2023) for the precise control of timing under neuromuscular paralysis for surgical patients
- The interim analysis evaluated the patient’s intubating conditions post administering BX1000 in a blinded manner. In the 20-patient cohort, 5 patients per group received one of the study medications
- The results depicted that all 20 patients met the 1EP of good/excellent intubating conditions at 60sec. out of which 20 were intubated following assessment at 60sec. & 1 at 90sec.
Ref: GlobeNewswire | Image: Baudax
Related News:- Baudax Bio's Anjeso Receives the US FDA's Approval to Manage Moderate to Severe Pain
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
